These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 24140122)

  • 41. HLA-DRB1*09 is associated with increased incidence of cytomegalovirus infection and disease after allogeneic hematopoietic stem cell transplantation.
    Du J; Liu J; Gu J; Zhu P
    Biol Blood Marrow Transplant; 2007 Dec; 13(12):1417-21. PubMed ID: 18022570
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Levels of CMV specific CD4 T cells are dynamic and correlate with CMV viremia after allogeneic stem cell transplantation.
    Widmann T; Sester U; Gärtner BC; Schubert J; Pfreundschuh M; Köhler H; Sester M
    PLoS One; 2008; 3(11):e3634. PubMed ID: 18982061
    [TBL] [Abstract][Full Text] [Related]  

  • 43. L-index as a novel index to evaluate both the intensity and duration of lymphopenia after allogeneic hematopoietic stem cell transplantation.
    Kimura SI; Wada H; Sakamoto K; Ashizawa M; Sato M; Terasako K; Nakasone H; Kikuchi M; Okuda S; Kako S; Yamazaki R; Oshima K; Tanaka Y; Tanihara A; Nishida J; Kanda Y
    Transpl Infect Dis; 2012 Aug; 14(4):364-73. PubMed ID: 22469427
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cytomegalovirus shedding in the oral cavity of allogeneic haematopoietic stem cell transplant patients.
    Correia-Silva Jde F; Victória JM; Guimarães AL; Salomão UE; de Abreu MH; Bittencourt H; Gomez RS
    Oral Dis; 2007 Mar; 13(2):163-9. PubMed ID: 17305617
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Fludarabine-based reduced intensity conditioning transplants have a higher incidence of cytomegalovirus reactivation compared with myeloablative transplants.
    George B; Kerridge I; Gilroy N; Huang G; Hertzberg M; Gottlieb D; Bradstock K
    Bone Marrow Transplant; 2010 May; 45(5):849-55. PubMed ID: 19915635
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Kinetics of interferon-gamma producing cytomegalovirus (CMV)-specific CD4+ and CD8+ T lymphocytes and the risk of subsequent CMV viremia after allogeneic hematopoietic stem cell transplantation.
    Eid AJ; Brown RA; Hogan WJ; Lahr BD; Eckel-Passow JE; Litzow MR; Razonable RR
    Transpl Infect Dis; 2009 Dec; 11(6):519-28. PubMed ID: 19744286
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Cytomegalovirus-specific cellular immune responses and viremia in recipients of allogeneic stem cell transplants.
    Aubert G; Hassan-Walker AF; Madrigal JA; Emery VC; Morte C; Grace S; Koh MB; Potter M; Prentice HG; Dodi IA; Travers PJ
    J Infect Dis; 2001 Oct; 184(8):955-63. PubMed ID: 11574909
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Lymphocyte reconstitution following allogeneic hematopoietic stem cell transplantation: a retrospective study including 148 patients.
    Heining C; Spyridonidis A; Bernhardt E; Schulte-Mönting J; Behringer D; Grüllich C; Jakob A; Bertz H; Finke J
    Bone Marrow Transplant; 2007 May; 39(10):613-22. PubMed ID: 17384658
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Cytomegalovirus diseases after allogeneic hematopoietic stem cell transplantation (Allo-HSCT) and related risk factors].
    Huang XJ; Xu LP; Ren HY; Zhang YC; Guo NL; Lu DP
    Zhonghua Yi Xue Za Zhi; 2003 May; 83(9):766-9. PubMed ID: 12899755
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Impact of cytomegalovirus replication and cytomegalovirus serostatus on the outcome of patients with B cell lymphoma after allogeneic stem cell transplantation.
    Mariotti J; Maura F; Spina F; Roncari L; Dodero A; Farina L; Montefusco V; Carniti C; Sarina B; Patriarca F; Rambaldi A; Onida F; Olivieri A; Zallio F; Corradini P
    Biol Blood Marrow Transplant; 2014 Jun; 20(6):885-90. PubMed ID: 24583412
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Risk factors for progression from cytomegalovirus viremia to cytomegalovirus disease after allogeneic hematopoietic stem cell transplantation.
    Jang JE; Hyun SY; Kim YD; Yoon SH; Hwang DY; Kim SJ; Kim Y; Kim JS; Cheong JW; Min YH
    Biol Blood Marrow Transplant; 2012 Jun; 18(6):881-6. PubMed ID: 22062802
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Diagnostic utility of human cytomegalovirus-specific T-cell response monitoring in predicting viremia in pediatric allogeneic stem-cell transplant patients.
    Abate D; Cesaro S; Cofano S; Fiscon M; Saldan A; Varotto S; Mengoli C; Pillon M; Calore E; Biasolo MA; Cusinato R; Barzon L; Messina C; Carli M; Palù G
    Transplantation; 2012 Mar; 93(5):536-42. PubMed ID: 22314338
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Ex vivo monitoring of human cytomegalovirus-specific CD8(+) T-Cell responses using the QuantiFERON-CMV assay in allogeneic hematopoietic stem cell transplant recipients attending an Irish hospital.
    Fleming T; Dunne J; Crowley B
    J Med Virol; 2010 Mar; 82(3):433-40. PubMed ID: 20087937
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Impact of initial cytomegalovirus viral load on efficacy of preemptive therapy with ganciclovir in allogeneic stem cell transplant recipients].
    Torre-Cisneros J; Caston-Osorio JJ; Martín C; Rivero A; Doblas A; Rojas R; Gómez P; Martínez F; Torres A
    Enferm Infecc Microbiol Clin; 2010 Jan; 28(1):6-12. PubMed ID: 19409666
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Appearance of cytomegalovirus-specific T-cells predicts fast resolution of viremia post hematopoietic stem cell transplantation.
    Pelák O; Stuchlý J; Król L; Hubáček P; Keslová P; Sedláček P; Formánková R; Starý J; Hrušák O; Kalina T
    Cytometry B Clin Cytom; 2017 Sep; 92(5):380-388. PubMed ID: 26647177
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Cytomegalovirus (CMV) DNA load in plasma for the diagnosis of CMV disease before engraftment in hematopoietic stem-cell transplant recipients.
    Limaye AP; Huang ML; Leisenring W; Stensland L; Corey L; Boeckh M
    J Infect Dis; 2001 Feb; 183(3):377-82. PubMed ID: 11133368
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A randomized trial of high dose polyvalent intravenous immunoglobulin (HDIgG) vs. Cytomegalovirus (CMV) hyperimmune IgG in allogeneic hemopoietic stem cell transplants (HSCT).
    Zikos P; Van Lint MT; Lamparelli T; Gualandi F; Occhini D; Mordini N; Berisso G; Bregante S; Bacigalupo A
    Haematologica; 1998 Feb; 83(2):132-7. PubMed ID: 9549924
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Impact of CMV and EBV on Immune Recovery After Allogeneic Hematopoietic Cell Transplantation in Children.
    Pukownik E; Kubicka M; Kurylo-Rafinska B; Debski R; Galazka P; Czyzewski K; Krenska A; Bartoszewicz N; Demidowicz E; Marjańska A; Dziedzic M; Pogorzala M; Wysocki M; Styczynski J
    Anticancer Res; 2018 Oct; 38(10):6009-6013. PubMed ID: 30275233
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Cytomegalovirus Reactivation Is Associated with Increased Risk of Late-Onset Invasive Fungal Disease after Allogeneic Hematopoietic Stem Cell Transplantation: A Multicenter Study in the Current Era of Viral Load Monitoring.
    Yong MK; Ananda-Rajah M; Cameron PU; Morrissey CO; Spencer A; Ritchie D; Cheng AC; Lewin SR; Slavin M
    Biol Blood Marrow Transplant; 2017 Nov; 23(11):1961-1967. PubMed ID: 28797778
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.